肝性脳症(HE)治療薬の世界市場2018-2022:NAD、抗生物質、その他
About Hepatic Encephalopathy (HE) Therapeutics
HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.
Technavio’s analysts forecast the global hepatic encephalopathy (HE) therapeutics market to grow at a CAGR of 5.35% during the period 2018-2022.
[Covered in this report]
The report covers the present scenario and the growth prospects of the global hepatic encephalopathy (HE) therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio’s report, Global Hepatic Encephalopathy (HE) Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
[Key vendors]
• ASKA Pharmaceutical
• COSMO PHARMACEUTICALS
• Mallinckrodt
• Valeant
[Market driver]
• Availability of patient-focused programs to assist disease management
• For a full, detailed list, view our report
[Market challenge]
• Late and inaccurate diagnosis
• For a full, detailed list, view our report
[Market trend]
• Technological advances
• For a full, detailed list, view our report
[Key questions answered in this report]
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.